Who Paid My Doc
Diego Saporta
Otolaryngic Allergy Elizabeth, NJ Medical Doctor
NPI 1164423299 CMS profile 279598
470 North Ave, Elizabeth, NJ 07208
General payments
$783
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Diego Saporta of Elizabeth, NJ is reported in the CMS Open Payments database as having received $783 across 44 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $201 | 8 | |
| 2022 | General | $329 | 19 | |
| 2021 | General | $144 | 10 | |
| 2019 | General | $109 | 7 |
Beside peers
- Diego Saporta
- Otolaryngic Allergy median
- Middle half of Otolaryngic Allergy
- National median
In program year 2025, general payments to Diego Saporta were reported at $0. Among 69 Otolaryngic Allergy profiles paid that year, the median was $420 and the middle half received between $149 and $981.
Show as a table
| Year | Diego Saporta | Otolaryngic Allergy median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $109 | $206 | $52–$646 | $163 |
| 2020 | $0 | $158 | $40–$529 | $114 |
| 2021 | $144 | $225 | $68–$696 | $132 |
| 2022 | $329 | $364 | $108–$1,004 | $149 |
| 2023 | $201 | $272 | $123–$1,038 | $160 |
| 2024 | $0 | $416 | $129–$1,844 | $164 |
| 2025 | $0 | $420 | $149–$981 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 7 drugsPart D claims
116
Drug cost
$3,879
Branded share of claims
33.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Np Thyroid Thyroid,pork | Brand | 28 | $1,901 | |
| Ciprofloxacin-Dexamethasone Ciprofloxacin Hcl/Dexameth | Brand | 11 | $1,121 | |
| Liothyronine Sodium | Generic | 12 | $356 | |
| Mometasone Furoate | Generic | 12 | $223 | |
| Montelukast Sodium | Generic | 17 | $162 | |
| Levocetirizine Dihydrochloride | Generic | 23 | $109 | |
| Prednisone | Generic | 13 | $8 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.
Records
44 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Otolaryngic Allergy in New Jersey
Related records
Otolaryngic Allergy in New Jersey
Practitioners in the same specialty and state, ranked by reported value.
All Otolaryngic Allergy
Everyone recorded under this specialty, nationwide.
Doctors in New Jersey
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.